Medexus Schedules Second Fiscal Quarter 2026 Conference Call

Rhea-AI Summary

Medexus Pharmaceuticals (OTCQX: MEDXF) will hold a conference call at 8:00 AM ET on Thursday, November 13, 2025 to discuss results for the second fiscal quarter ended September 30, 2025. The company expects to file its financial statements and MD&A after markets close on November 12, 2025.

Live dial-in numbers are provided for Canadian/U.S. and international callers with Access Code 988000. A live webcast will be available on the Investors section of Medexus's website and a replay will be available by phone and online through Friday, November 13, 2026.

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 13, 2025 to discuss Medexus's results for its second fiscal quarter ended September 30, 2025. Medexus expects to file its financial statements and MD&A after markets close on November 12, 2025.

To participate in the call, please dial the following numbers:

877-545-0523 (toll-free) for Canadian and U.S. callers
+1 973-528-0016 for international callers

Access code: 988000

A live webcast of the call will be available on the Investors section of Medexus's corporate website or at the following link:

https://www.webcaster5.com/Webcast/Page/2010/53180

A replay of the call will be available approximately one hour following the end of the call through Thursday, November 20, 2025. To access the replay, please dial the following numbers -

877-481-4010 for Canadian and U.S. callers
+1 919-882-2331 for international callers

Conference ID: 53180

A replay of the webcast will be available on the Investors section of Medexus's corporate website until Friday, November 13, 2026.

About Medexus

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and rheumatology, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.

Contacts

Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com

Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com

Victoria Rutherford | Adelaide Capital
Tel: 480-625-5772 | Email: victoria@adcap.ca

Forward-looking statements

Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273015

FAQ

When is Medexus (MEDXF) holding its Q2 2026 conference call?

The call is scheduled for 8:00 AM ET on Thursday, November 13, 2025.

When will Medexus (MEDXF) file its Q2 2026 financial statements and MD&A?

Medexus expects to file its financial statements and MD&A after markets close on November 12, 2025.

How can investors join the Medexus (MEDXF) conference call?

Dial 877-545-0523 (Canada/U.S.) or +1 973-528-0016 (international) and use Access Code 988000, or join the live webcast on the company's Investors website.

Where can I find the Medexus (MEDXF) live webcast and replay?

The live webcast and replay are available on the company's Investors section; the webcast link is provided on the investor site and a replay will be available online through November 13, 2026.

How long will the phone replay of the Medexus (MEDXF) call be available?

The phone replay is available approximately one hour after the call ends through Thursday, November 20, 2025.

What will Medexus (MEDXF) discuss on the November 13, 2025 call?

Management will discuss results for the second fiscal quarter ended September 30, 2025.